Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPYVLP01 + aluminum hydroxide
- Development stage
- Unknown
- Lead developer
- SpyBiotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SPYVLP01 + aluminum hydroxide** is a combination vaccine candidate targeting human cytomegalovirus (HCMV). The primary component, **SPYVLP01**, is a virus-like particle (VLP) vaccine that employs SpyBiotech’s Hepatitis B VLP platform with protein 'superglue' technology, designed to enhance immunogenicity through stable antigen binding[3][5]. Aluminum hydroxide serves as an adjuvant, boosting the immune response to the contained antigens[8]. SPYVLP01 expresses selected HCMV antigens (including gB and possibly ppUL83/IE1 proteins) to trigger both antibody and T-cell responses to prevent or reduce HCMV infection. Developed by SpyBiotech and tested in healthy adults, no approved HCMV vaccine is currently available[3].
- Other names
- SPYVLP01 + Alhydrogel
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)gB (Human cytomegalovirus glycoprotein B)IE1 (HCMV immediate-early protein 1)
Beyond the preview
Go deeper on SPYVLP01 + aluminum hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPYVLP01 + aluminum hydroxide.